Chlorambucil
Leukeran (chlorambucil) is a small molecule pharmaceutical. Chlorambucil was first approved as Leukeran on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, breast neoplasms, choriocarcinoma, hodgkin disease, and non-hodgkin lymphoma amongst others in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Leukeran
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorambucil
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LEUKERAN | WOODWARD SPECL | N-010669 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| leukeran | New Drug Application | 2023-05-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| b-cell chronic lymphocytic leukemia | — | D015451 | C91.1 |
| breast neoplasms | EFO_0003869 | D001943 | C50 |
| choriocarcinoma | — | D002822 | C58 |
| hodgkin disease | — | D006689 | C81 |
| non-hodgkin lymphoma | — | D008228 | C85.9 |
| ovarian neoplasms | EFO_0003893 | D010051 | C56 |
| testicular neoplasms | — | D013736 | C62 |
| thrombocytosis | — | D013922 | D75.83 |
| waldenstrom macroglobulinemia | — | D008258 | C88.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0172 | Chlorambucil, oral, 2 mg |
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | — | 1 | 5 | — | 2 | 8 | |
| Leukemia | D007938 | C95 | — | — | 3 | — | — | 3 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | — | 1 | 1 | — | — | 2 | |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | — | 1 | — | — | 1 |
| Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | — | 1 | — | — | 1 | |
| Neoplasms | D009369 | C80 | — | — | 1 | — | — | 1 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | — | — | 1 | — | — | 1 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | 1 | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CHLORAMBUCIL |
| INN | chlorambucil |
| Description | Chlorambucil is a monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia. It has a role as an alkylating agent, a carcinogenic agent, an antineoplastic agent, an immunosuppressive agent and a drug allergen. It is a nitrogen mustard, an organochlorine compound, an aromatic amine, a tertiary amino compound and a monocarboxylic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 305-03-3 |
| RxCUI | 2346 |
| ChEMBL ID | CHEMBL515 |
| ChEBI ID | 28830 |
| PubChem CID | 2708 |
| DrugBank | DB00291 |
| UNII ID | 18D0SL7309 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,317 documents
View more details
Safety
Black-box Warning
Black-box warning for: Leukeran
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
238 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more